Insights - It’s been a banner year in biotech, and one of PropThink’s top picks in 2013, Keryx Biopharmaceuticals (KERX), has outperformed significantly as one of the … Continue Reading
Read nowResearch - When investing in development-stage biotech companies, evidence of success is everything. Therefore, investors should always start with the question: Is the company’s product candidate a … Continue Reading
Read nowRecap - Endo Health Solutions (ENDP) announced plans on Tuesday to purchase Paladin Labs (PLB.TO), a Canadian specialty pharmaceutical manufacturer, for $1.5 billion. ENDP fell significantly in 2012 on … Continue Reading
Read nowResearch - Keryx Biopharmaceuticals (KERX) announced on Tuesday that a phase 2 study of Zerenex (ferric citrate) in non-dialysis dependent chronic kidney disease (CKD) patients with elevated … Continue Reading
Read nowLong Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read nowLong Ideas - Early this year, Keryx Biopharmaceuticals (KERX) reported strong Phase III results for its phosphate binder Zerenex (ferric citrate) in dialysis patients, sending the stock from … Continue Reading
Read nowMost Popular - The FDA accepted Durect’s (DRRX) New Drug Application for Posidur on Thursday, causing shares to gap up and continue higher through the day. Analysts expect … Continue Reading
Read now
